Comprehensive Cell Solutions (CCS) has been pioneering advances in the research, development, and manufacture of cell therapies: A business unit of New York Blood Center Enterprises (NYBCe), CCS is a cell and gene therapy-focused development and manufacturing organization that provides critical capacity to an underserved population of early-stage developers, as well as expertise and a strategic footprint for hospital treatment centers and pharmaceutical organizations. In 2023, CCS announced the acquisition of commercial-scale cell and gene therapy development and manufacturing facilities, as well as certain technologies and equipment from Talaris in Houston, Texas, and Louisville, Kentucky. Visit our website to learn more & connect with us!